Alan Kwan

Dr. Alan Kwan joined QLS Advisors in 2022 and serves as Portfolio Manager, Biotechnology and Pharmaceuticals, with responsibility for trading strategies innovation and the optimized integration of fundamental analysis into those strategies, where appropriate. Dr. Kwan previously served as an Analyst at Millennium Management, LLC where he designed, managed, and implemented semi-automated infrastructure to support several fundamentals-based trading strategies for his coverage in both large and SMID cap biopharma US equities. Prior to joining Millennium, Dr. Kwan served as a Vice President of Research at Tekla Capital Management where he covered both public and private healthcare investments. His public coverage spanned SMID cap biotechnology, all cap life-science tools, all cap diagnostics, and all cap medical devices. In private investments, he was responsible for the evaluating opportunities in biotechnology, life-science tools and diagnostics, and medical devices and served as a board observer on select portfolio companies. He received his B.S. in Computer Science from the University of British Columbia, his M.S. in Computer Science from Washington University in St. Louis, his Ph.D. in Computational Genomics from Washington University School of Medicine, and his MBA from MIT.